![Debra Stephanie Barker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Debra Stephanie Barker
Director/Miembro de la Junta en
CUREVAC
.
Perfil
Debra Stephanie Barker is currently Non-Executive Director at CureVac SE, Senior Independent Non-Executive Director at Arix Bioscience Plc since 2022, Director at Hutman Diagnostics AG, Senior Independent Director at Arix Bioscience since 2022, and Member of the Supervisory Board at CureVac NV since 2022.
Former roles include Chief Executive Officer & Director at Destiny Pharma Plc in 2023, Non-Executive Director at Oncoinvent ASA, Head of Development for Anti-Infectives & Immunology at Novartis AG, and Chief Medical & Development Officer at Spexis Ltd. from 2017 to 2018.
Education includes graduate studies at King's College London and a doctorate from Queens' College Cambridge.
Cargos activos de Debra Stephanie Barker
| Empresas | Cargo | Inicio |
|---|---|---|
| CUREVAC | Director/Miembro de la Junta | 22/06/2022 |
| ARIX BIOSCIENCE PLC | Director/Miembro de la Junta | 10/08/2022 |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Operates as an in vitro diagnostics product development and portfolio management company | Director/Miembro de la Junta | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Director/Miembro de la Junta | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience invests in companies located in the United Kingdom. The firm focuses on the therapeutics sector. It participates in early stage capital requirements. | Director/Miembro de la Junta | 01/08/2022 |
Antiguos cargos conocidos de Debra Stephanie Barker.
| Empresas | Cargo | Fin |
|---|---|---|
| SPEXIS AG | Director Técnico/Científico/I+D | 31/12/2018 |
| DESY PHAR | Director Ejecutivo | 01/09/2023 |
| ONCOINVENT ASA | Director/Miembro de la Junta | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formación de Debra Stephanie Barker.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
11
Relaciones de 1er grado
11
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 11 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Spexis Ltd.
 Spexis Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that focuses on the discovery and development of macrocycle drugs addressing unmet medical needs | Health Technology |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Destiny Pharma Plc
 Destiny Pharma Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops novel antimicrobial products | Health Technology |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
Queens' College Cambridge
 Queens' College Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Arix Bioscience Plc
 Arix Bioscience Plc Investment ManagersFinance Operates as a global venture capital firm | Finance |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Operates as an in vitro diagnostics product development and portfolio management company | Health Technology |
CureVac NV
 CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience invests in companies located in the United Kingdom. The firm focuses on the therapeutics sector. It participates in early stage capital requirements. | Finance |
- Bolsa de valores
- Insiders
- Debra Stephanie Barker
Elige MarketScreener 
